Table of Contents
Glipizide is a medication primarily used to manage blood sugar levels in people with type 2 diabetes. It belongs to the class of drugs known as sulfonylureas, which stimulate the pancreas to produce more insulin. Understanding the common brand names and the federal regulations surrounding glipizide is essential for healthcare providers, patients, and educators alike.
Common Brand Names of Glipizide
- Glucotrol
- Glucotrol XL
- Glipizide ER
- Glipizide IR
These brand names are marketed by various pharmaceutical companies and may vary by region or country. The “XL” or “ER” suffix indicates extended-release formulations designed for once-daily dosing, providing a steady release of the medication over time.
Federal Regulations Governing Glipizide
Glipizide is classified as a prescription drug by the U.S. Food and Drug Administration (FDA). Its approval process involves rigorous evaluation of safety, efficacy, and manufacturing standards. Several federal regulations govern its production, distribution, and use:
- FDA Approval: Ensures the medication is safe and effective for its intended use.
- Prescription Requirement: Only available through a licensed healthcare provider.
- Manufacturing Standards: Must comply with Good Manufacturing Practices (GMP).
- Labeling Regulations: Accurate and comprehensive information about dosage, side effects, and contraindications.
- Controlled Substance Laws: Glipizide is not a controlled substance but is regulated to prevent misuse and abuse.
Additional Regulatory Considerations
Federal regulations also include monitoring for adverse effects and post-marketing surveillance. The FDA can withdraw approval if new safety concerns arise. Patients are advised to adhere strictly to prescribed dosages and consult healthcare providers for any concerns or side effects.
Conclusion
Understanding the common brand names and federal regulations related to glipizide helps ensure safe and effective use of the medication. Healthcare professionals should stay informed about regulatory updates, while patients should follow their prescribed treatment plans carefully.